The latter was also true for the data from an indirect comparison: Here, the manufacturer analysed studies that compared either eribulin or trabectedin
with dacarbazine.
Not exact matches
In the control arm,
dacarbazine was not used in compliance
with the approval, however: Instead of administration in combination
with another drug (doxorubicin),
dacarbazine was used as monotherapy, and a different dosage was used in the beginning of the treatment.
Plerixafor in combination
with the chemotherapeutic agent
dacarbazine significantly suppressed the metastatic phenotype of melanoma compared to
dacarbazine alone [40].
The MEK inhibitor binimetinib resulted in improved progression - free survival and response rates vs
dacarbazine in patients
with NRAS - mutated metastatic melanoma.